Harvard Study Says P-tau217 Blood Test Predicts Alzheimer's Risk 10 Years Ahead
Updated
Updated · Fox News · Jul 18
Harvard Study Says P-tau217 Blood Test Predicts Alzheimer's Risk 10 Years Ahead
3 articles · Updated · Fox News · Jul 18
Summary
Nearly 2,700 symptom-free adults were followed for up to 10 years, and those with very high p-tau217 levels had a 78% estimated risk of cognitive impairment within a decade.
The Harvard-led study, presented in London and published in JAMA, found the blood marker added predictive power beyond standard brain scans and genetic testing.
Moderately elevated p-tau217 still signaled a 45% 10-year risk, suggesting the test could identify older adults years before noticeable memory problems begin.
Researchers said the test could help enroll prevention-trial patients and eventually guide monitoring and treatment, but warned risk estimates still need validation in longer, more diverse studies.
This blood test predicts Alzheimer's risk years in advance, but what can you actually do with that information right now?
A new test predicts Alzheimer's a decade early. Is this a medical breakthrough or the start of a decade of anxiety?
The p-tau217 Blood Test: Transforming Alzheimer’s Diagnosis, Prediction, and Ethical Care
Overview
Alzheimer's disease diagnosis is changing rapidly thanks to advancements in blood-based biomarkers like the p-tau217 test. This test marks a major step forward by providing new insights into a person's risk and the likely timing of symptom onset. International studies have highlighted the strong predictive value of p-tau217, showing it can estimate when symptoms may appear, even in people without current cognitive problems. These breakthroughs are making diagnosis less invasive and more accessible, setting the stage for earlier detection, better prevention strategies, and a new era in Alzheimer's care.